JUL 02, 2017 12:08 PM PDT

FDA Trying to Eliminate Backlog of Orphan Drug Requests

WRITTEN BY: Carmen Leitch

There are many rare diseases in existence, some with only a handful of people that suffer with them, usually for their entire lives. It’s not a big priority for many drug companies to spend a lot of money on the research and development of new drugs for rare diseases, and it can become prohibitively expensive for companies that are concerned about the profits of shareholders to continue to manufacture drugs that not many people use. The U.S. Food and Drug Administration is attempting to address this issue that may not affect many people, but is life-changing for those that are impacted.

The FDA has announced the formulation of a plan to eliminate the backlog of existing orphan designation requests for drugs. The Orphan Drug Designation Program assigns orphan status when less than 200,000 patients are using drugs and therapeutics that are designed for the safe and effective prevention, treatment or diagnosis of a disease; one with that number of patients is considered rare.

The FDA has committed to both eliminate the backlog as well as ensuring that new requests for orphan drug designation receive a timely response, slated to be within 90 days.

"People who suffer with rare diseases are too often faced with no, or limited, treatment options, and what treatment options they have may be quite expensive due in part to significant costs of developing therapies for smaller populations," commented Dr. Scott Gottlieb, the Commissioner of the FDA. "Congress gave us tools to incentivize the development of novel therapies for rare diseases and we intend to use these resources to their fullest extent in order to ensure Americans get the safe and effective medicines they need, and that the process for developing these innovations is as modern and efficient as possible."

Credit: Pixabay

Currently, there are around 200 orphan drug designation requests that the FDA has yet to review, although it is noteworthy that the number has increased steadily over the past five years. From 2015 to 2016, the number of submitted requests more than doubled.

The agency has a new strategy, called the Medical Innovation Development Plan, which aims to modernize the regulatory tools that are utilized by the FDA. The plan strives to make FDA policies more efficient and risk-based. There are also plans to reorganize the staff in charge of so that expertise and efficiency of workload are maximized. This work will help establish a new FDA Orphan Products Council that will be able to tackle new scientific and regulatory issues.

The FDA will also be creating a Backlog SWAT team of senior reviewers that have a notable expertise in the designation of orphan drugs, one which will be solely working on the backlogged applications and will start with the oldest requests.

There has been legislation that has tried to ddress this issue; it incentivizes the development of orphan drugs by giving the developers a longer period during whcih they alone can manufacture and sell it. As such, it drives the cost of those drugs up because there is no competition in the market. A complex issue to be sure, check out the video below to learn one opinion about its efficacy.

Source: UPI, US FDA

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
MAY 10, 2021
Coronavirus
Researchers Create a Vaccine For Multiple SARS Viruses, Including COVID-19 & Variants
MAY 10, 2021
Researchers Create a Vaccine For Multiple SARS Viruses, Including COVID-19 & Variants
The pandemic virus SARS-CoV-2 has changed the world in devastating ways, taking hundreds of thousands of lives & new var ...
MAY 15, 2021
Drug Discovery & Development
New Weight Loss Drug Converts Energy-Storing Fat into Energy-Burning Fat
MAY 15, 2021
New Weight Loss Drug Converts Energy-Storing Fat into Energy-Burning Fat
According to the World Health Organization (WHO), in 2016, around 2 billion adults around the world were overweight ...
MAY 30, 2021
Microbiology
The Mechanics of a Gliding Microbe, Revealed
MAY 30, 2021
The Mechanics of a Gliding Microbe, Revealed
Humans have been able to use machines to master movement, but there are many organisms that can get around just fine on ...
JUN 04, 2021
Drug Discovery & Development
Stem Cell Transplants May Treat Patients with Type 2 Diabetes
JUN 04, 2021
Stem Cell Transplants May Treat Patients with Type 2 Diabetes
Researchers at the Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam have found that stem cel ...
JUN 06, 2021
Cell & Molecular Biology
Caught in the Act of RNA Transcription
JUN 06, 2021
Caught in the Act of RNA Transcription
Researchers have now been able to capture an enzyme called RNA polymerase on video as it copies a DNA sequence into an R ...
JUN 11, 2021
Cell & Molecular Biology
Bad Fat in the Tumor Microenvironment May Disrupt Killer T Cells
JUN 11, 2021
Bad Fat in the Tumor Microenvironment May Disrupt Killer T Cells
The immune system can detect and destroy pathogenic and cancerous cells, but sometimes those dangerous cells can evade t ...
Loading Comments...